Corrigendum: Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum

Front Med (Lausanne). 2024 Sep 10:11:1462054. doi: 10.3389/fmed.2024.1462054. eCollection 2024.

Abstract

[This corrects the article DOI: 10.3389/fmed.2023.1156557.].

Keywords: ankylosing spondylitis; axial spondyloarthritis; effectiveness; non-radiographic axial spondyloarthritis; real-world evidence; secukinumab.

Publication types

  • Published Erratum

Grants and funding

“The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study received funding from Novartis Farmacéutica, S.A”.